Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H3VI
|
|||
| Drug Name |
PMID25656651-Compound-31a
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG BURGER, Matthew DING, Yu HAN, Wooseok LINDVALL, Mika NISHIGUCHI, Gisele A. RICO, Alice SMITH, Aaron TANNER, Huw WAN, Lifeng
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H23N5O3
|
|||
| Canonical SMILES |
C=C1C(CC(OC12CC2)C3=C(C=NC=C3)NC(=O)C4=NC(=CN=C4N)C5=CC=CC=C5)O
|
|||
| InChI |
1S/C24H23N5O3/c1-14-19(30)11-20(32-24(14)8-9-24)16-7-10-26-12-18(16)29-23(31)21-22(25)27-13-17(28-21)15-5-3-2-4-6-15/h2-7,10,12-13,19-20,30H,1,8-9,11H2,(H2,25,27)(H,29,31)/t19-,20-/m0/s1
|
|||
| InChIKey |
WHESOVNDWAKAQI-PMACEKPBSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target's Patent Info | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.